Sandbox: prognosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
Line 1: Line 1:
* The table below lists prognostic factors for chronic lymphocytic leukemia:<ref>Hoffbrand V, Moss P. Essential Haematology. John Wiley & Sons; 2011</ref>
* The table below lists prognostic factors for chronic lymphocytic leukemia:<ref name="pmid25461996">{{cite journal| author=Nabhan C, Rosen ST| title=Chronic lymphocytic leukemia: a clinical review. | journal=JAMA | year= 2014 | volume= 312 | issue= 21 | pages= 2265-76 | pmid=25461996 | doi=10.1001/jama.2014.14553 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25461996  }} </ref><ref>Hoffbrand V, Moss P. Essential Haematology. John Wiley & Sons; 2011</ref>


{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px"
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px"
Line 10: Line 10:
|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Gender'''|| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Age'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:* Males are associated with a worse prognosis
:* Older age of diagnosis is associated with a worse prognosis.
 
|-
 
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Gender'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:* Males are associated with a worse prognosis.
|-
 
 
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Performance status'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:* Patient's poor performance status is associated with a worse prognosis.
|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Stage'''|| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Stage'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:*Binet stages B and C or Rai stages II–IV are associated with a worse prognosis  
:*Binet stages B and C or Rai stages II–IV are associated with a worse prognosis.


|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte doubling time'''|| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte doubling time'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:*Deletion of chromosome 17 short arm is associated with a worse prognosis  
:*A rapid lymphocyte doubling time is associated with a worse prognosis


|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Genetic mutations'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Genetic mutations'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*Deletion of chromosome 17 short arm is associated with a worse prognosis  
:*Deletion of chromosome 17 short arm is associated with a worse prognosis.
 
|-
|-


|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Prolymphocytes percent'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:*An increased percentage of prolymphocytes is associated with a worse prongnosis.
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Histological analysis'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Histological analysis'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*Diffuse histology on bone marrow aspiration is associated with a worse prognosis  
:*Diffuse histology on bone marrow aspiration is associated with a worse prognosis.


|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lactate dehydrogenase (LDH) level'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lactate dehydrogenase (LDH) level'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*Elevated levels of LDH is associated with a worse prognosis
:*Elevated levels of LDH are associated with a worse prognosis.
 
|-
 
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''β2-microglobulin level '''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*Elevated levels of β2-microglobulin level are associated with a worse prognosis.


|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte surface marker'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte surface marker'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*Positive expression of CD38 is associated with a worse prognosis
:*Positive expression of CD38 is associated with a worse prognosis.
|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Immunoglobulin (Ig)VH gene'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Immunoglobulin (Ig)VH gene'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*The absence of VH gene mutation is associated with a worse prognosis
:*The absence of VH gene mutation is associated with a worse prognosis.


|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Membrane-bound proteins'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Membrane-bound proteins'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*The expression of Zeta-chain-associated protein kinase 70 (ZAP)is associated with a poor prognosis
:*The expression of Zeta-chain-associated protein kinase 70 (ZAP) is associated with a poor prognosis.
|}
|}

Latest revision as of 00:04, 14 October 2015

  • The table below lists prognostic factors for chronic lymphocytic leukemia:[1][2]
Prognostic Factor Description
Age
  • Older age of diagnosis is associated with a worse prognosis.
Gender
  • Males are associated with a worse prognosis.
Performance status
  • Patient's poor performance status is associated with a worse prognosis.
Stage
  • Binet stages B and C or Rai stages II–IV are associated with a worse prognosis.
Lymphocyte doubling time
  • A rapid lymphocyte doubling time is associated with a worse prognosis
Genetic mutations
  • Deletion of chromosome 17 short arm is associated with a worse prognosis.
Prolymphocytes percent
  • An increased percentage of prolymphocytes is associated with a worse prongnosis.
Histological analysis
  • Diffuse histology on bone marrow aspiration is associated with a worse prognosis.
Lactate dehydrogenase (LDH) level
  • Elevated levels of LDH are associated with a worse prognosis.
β2-microglobulin level
  • Elevated levels of β2-microglobulin level are associated with a worse prognosis.
Lymphocyte surface marker
  • Positive expression of CD38 is associated with a worse prognosis.
Immunoglobulin (Ig)VH gene
  • The absence of VH gene mutation is associated with a worse prognosis.
Membrane-bound proteins
  • The expression of Zeta-chain-associated protein kinase 70 (ZAP) is associated with a poor prognosis.
  1. ↑ Nabhan C, Rosen ST (2014). "Chronic lymphocytic leukemia: a clinical review". JAMA. 312 (21): 2265–76. doi:10.1001/jama.2014.14553. PMID 25461996.
  2. ↑ Hoffbrand V, Moss P. Essential Haematology. John Wiley & Sons; 2011
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox:_prognosis&oldid=1174331"